Madrigal Pharmaceuticals Inc.
Income Statement
| Line Item | FY2017 | FY2012 |
|---|---|---|
| Revenue | $0 | $147.0K |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | — | — |
| SG&A Expense | $7.7M | $11.7M |
| Operating Income | $-32.1M | $-60.9M |
| Operating Margin | — | -41,456.5% |
| Interest Expense | — | — |
| Pretax Income | — | — |
| Income Tax Expense | — | — |
| Net Income | $-31.2M | $-62.8M |
| Net Margin | — | -42,714.3% |
| EPS (Basic) | $-2.54 | $-1.06 |
| EPS (Diluted) | $-2.54 | $-1.06 |
| Shares Outstanding (Basic) | 14.2M | 68.9M |
| Shares Outstanding (Diluted) | 14.2M | 68.9M |
| Dividends Per Share | — | — |